The purpose of this study is to develop a specific and efficient targeted gene therapy candidate approach for laryngeal carcinomas. Several promoters of human squamous cell carcinoma antigen 2(SCCA2), secretory leukocyte protease inhibitor (SLPI) and Survivin genes were cloned from human genomic DNA and evaluated for tumor-specific transcription potential in human laryngeal carcinoma Hep-2 cells by dual luciferase assays. One SLPI promoter fragment (677 bp) showed the highest efficiency and specificity, and was used to control the expression of a recombinant active caspases-3 (revCasp3), which could trigger apoptosis without activation of its upstream cascade elements once expressed in a cell, in an adenoviral vector (Ad-SLPI-revCasp3), and its antitumor efficacy was assessed. In vitro infection with Ad-SLPI-revCasp3 showed revCasp3 could be specifically expressed in Hep-2 cells, resulting in efficient activation of endogenous Caspase-3 and subsequent apoptosis of Hep-2 cells. In Hep-2 nude mice xenograft model, intratumoral administration of Ad-SLPI-revCasp3 significantly inhibited tumor growth without obvious loss of body weight and obvious hepatic toxicity. In summary, our study showed the specific and efficient apoptosis-inducing potential of Ad-SLPI-revCasp3, and this makes it a new candidate approach of targeted gene therapy for laryngeal squamous cell carcinoma, which needs further systematic investigation.
INTRODUCTION
Laryngeal carcinoma is one of the most common cancers in head and neck, with 12 720 new cases diagnosed in 2010 in the United States, according to the data from Surveillance, Epidemiology and End Results in 2011. 1 The incidence is also gradually increasing. Despite advances in conventional therapy including surgery, chemotherapy and radiotherapy, the 5-year survival rate has not been significantly improved during the past decades. Big hurdles also lie in front of the therapeutic regimen for terminal relapsed cases: the tumor was unresectable due to invasion to the important blood vessels in head and neck or to the important cranial nerves, whereas the sensitivity to the administration of adjuvant radiotherapy and chemotherapy is rather low in squamous cell carcinoma. Therefore, local and regional disease control is important, and there is an urgent need for more effective, minimally invasive and lower toxic biotherapy in laryngeal carcinoma. 2 Currently, adenoviral vector-based approach is widely used in cancer gene therapy, including laryngeal carcinoma gene therapy, for its efficient gene delivery ability, by strategies of expressing various kinds of genes, such as tumor-suppressor genes, immune regulatory factors, suicide genes and so on. Although the growth of laryngeal cancer cells could be inhibited to a certain extent by adopting these strategies, no ideal strategy has yet been developed to achieve specific and potent antitumor efficacy while avoiding any adverse effects on normal cells. Therefore, targeted gene therapy strategies are being explored with increased targeted transduction of the recombinant viruses (by modifying the fiber knob), restricted expression of therapeutic genes (modulated by tumor-specific promoter) and therefore reduced the risk of nonspecific side effects on normal tissues. So far, controlled gene expression by tissue-specific promoters is one of the most effective ways for targeted gene therapy with adenovirus vectors. 3 For laryngeal carcinoma, however, no effective tissue-specific promoters have been reported. As 95% of the laryngeal carcinoma is composed of squamous cell carcinoma, the tissue-specific promoters for squamous cell carcinomas of other tissues could also be a suitable candidate for laryngeal carcinoma. In recent years, some researchers have reported the successful application of secretory leukocyte protease inhibitor (SLPI) promoter 4 and squamous cell carcinoma antigen 2 (SCCA2) promoter 5 in the targeted gene therapy in squamous cell carcinomas of ovarian cancer, lung cancer and others. Meanwhile, SLPI, SCCA2 were confirmed as potential biomarkers for laryngeal carcinoma, with significant overexpression in tumor tissues and extremely low expression in normal hepatic tissues. 6 --8 These studies have provided strong support for the rationale of the two promoters of SLPI and SCCA2 as tissuespecific promoters in laryngeal carcinoma cells, which might be useful in targeted gene therapy of laryngeal carcinoma.
A potent effector gene is critical in cancer gene therapy. Genes that can effectively induce apoptosis are good choices in this regard. Caspase-3, a member of the aspartate-specific cysteine protease family, has an important role in the no-return step of caspase-dependent apoptosis, and this makes it a potential candidate as an apoptosis-inducer in a wide range of malignant tumor cells. A constitutively active recombinant caspase-3, designated reversed-caspases-3 (revCasp3), which is generated by switching the order of its two subunits mimicking the structure of activated caspase-3, is capable of autocatalytic processing in an in vitro translation reaction and rapid induction of apoptosis in vivo without activation of its upstream elements. 9, 10 This makes it a powerful effector gene, in practice, for gene therapy of laryngeal carcinoma.
Interest in current study is to select the tissue-specific promoter with highest transcription efficiency in human laryngeal squamous cell carcinoma Hep-2 cells among the candidate promoters of SCCA2, SLPI and survivin, using human umbilical vein endothelial HUVEC cells and human osteosarcoma MG-63 cells as specificity controls, and to specifically induce the apoptosis of Hep-2 cells in vitro and inhibit the growth of laryngeal squamous cell carcinoma xenograft of Hep 2 cells by adenovirus vector-mediated expression of recombinant revCasp3 under the control of the selected promoter, testing the potential of this strategy in targeted gene therapy of human laryngeal carcinoma.
MATERIALS AND METHODS

Cell lines and animals
Human laryngeal squamous cell carcinoma Hep-2 cells were maintained in RPMI-1640 medium with 10% fetal bovine serum. Human osteosarcoma MG-63 cells, human vein endothelial cell HUVEC and human embryonic kidney cell HEK293 were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. All cells were cultured at 37 1C, 5% CO 2 and 100% humidity, and were split when confluent. In all, 22 BALB/c-nu mice, 5 --6 weeks old and 18 --20 g in weight, were bred in an aseptic condition and kept at a constant humidity (50 --80%) and temperature (18 --22 1C) according to standard guidelines.
Luciferase assay for promoters
As the transcriptional activity may vary differently for different regions of the promoter of secretory leukoprotease inhibitor (SLPI) in different cell lines, three fragments of SLPI promoter (SLPIa covers À849 to þ 22, SLPIb covers À650 to þ 22 and SLPIc covers À531 to þ 22), 11 as well as the core region of SCCA2 (À460 to 0) and survivin promoter (À1471 to À36) were amplified by specific primers. 12 All the primer sequences were listed in Table 1 . PCRs were performed using human genomic DNA as template. The resulting products were cloned into pGEM-T Easy vector (Promega, Madison, WI) and subjected to DNA sequencing. The verified promoter fragments were inserted into the upstream of the luciferase gene in vector pGL4.10 (Promega) to make plasmids pGL4.10-SLPIa, pGL4.10-SLPIb, pGL4.10-SLPIc, pGL4.10-SCCA2 and pGL4.10-Survivin. These plasmids were cotransfected separately with pGL4.74 into Hep-2 cell, HUVEC and MG-63 cells in triplicates to evaluate the transcription activity of different promoters using Dual-Luciferase Reporter Gene Assay Kit (Promega).
Generation of recombinant adenoviruses
The revCasp3 sequence was generated by joining the two subunits of caspase 3 in reversed order by similar strategy of the literature and cloned into pGEM-T Easy vector. Bovine growth hormone poly A signal from pcDNA3.1 ( þ ) vector was inserted into the multiple cloning site of adenoviral shuttle plasmid pDC312 vector (Microbix Biosystems, Toronto, Canada) to provide the terminal signal for transcription. The adenovirus backbone plasmid of pBGHlox(delta)E1,3Cre vector (Microbix Biosystems) was from the replication-defective adenovirus packaging system (Ad Max System).
SLPIb promoter was confirmed to be the most efficient and specific promoter in Hep-2 in current study. Therefore, the BglII/BamHI fragment of pGL4.10-SLPIb was subcloned into shuttle plasmid of pDC312-pA to make pDC312-SLPI-pA. The revCasp3 and GFP were cloned, respectively, into shuttle plasmid of pDC312-SLPI-pA after the SLPI promoter to generate plasmids pDC312-SLPI-revCasp3-pA and pDC312-SLPI-GFP-pA. These two shuttle plasmids were separately cotransfected with backbone plasmid pBGHlox (delta)E1,3Cre into HEK293 for packaging replication-deficient recombinant adenoviruses Ad-SLPI-revCasp3 and Ad-SLPI-GFP, respectively. The characterized recombinant adenoviruses were propagated in the HEK293 cells and purified by CsCl density gradient centrifugation and dialysis for 8 h at 4 1C with two changes of phosphate-buffered saline (PBS) containing 10% glycerol. Viral titers were determined by the method of TCID50 13 with HEK293 cells. Viruses were aliquoted and stored at À80 1C.
Characterization of recombinant adenovirus
PCR was performed to characterize the recombinant adenoviruses. A total of 50 ml of the supernantant from the second-generation viruses were used to extract DNA by adding 2 ml proteinase K, incubating for 30 min at 56 1C, placing in a boiling water bath for 10 min and quick cooling on ice. Primers for Ad-SLPI-revCasp3 were: upstream:
0 , and the expected PCR product size was 330 bp. Primers for Ad-SLPI-GFP were: upstream:
0 -GGAGCTGACACGGAAGAT-3 0 , and the expected PCR product size was 1482 bp. Western blot was performed to examine the protein level of active caspase-3 in Hep-2 cells 24 and 48 h after the infection of Ad-SLPIrevCasp3 and Ad-SLPI-GFP viruses at a multiplicity of infection of 50 pfu per cell. Meanwhile, fluorescence microscope was used to evaluate the expression of GFP in Hep-2 and HUVEC cells 24 and 48 h after the infection of Ad-SLPI-GFP.
Proliferation assay
The antiproliferative effect of recombinant adenoviruses on the Hep-2 cell line was evaluated using MTT assay. Briefly, 2 Â 10 3 cells in 100 ml of culture medium per well were seeded into 96-well flat-bottom plates. Cells were infected by Ad-SLPI-revCasp3 or Ad-SLPI-GFP at multiplicity of infection of 100, 50, 10, 0 pfu per cell, respectively, in triplicates. Following incubation for 72 h, 20 ml of 5 mg ml À1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were added into each well. After 4 h of incubation, the optical absorbance was measured on a microplate reader at 570 nm. 
Detection of apoptotic cells in vitro
DNA fragmentation and flow cytometry (ApoScreen Annexin V Apoptosis kit, Birmingham, AL) were used to evaluate the apoptosis of Hep-2 cells after infection by Ad-SLPI-revCasp3 and Ad-SLPI-GFP. In all, 4 Â 10 5 cells in 500 ml of culture medium per well were seeded into six-well flat-bottom plates. Cells were infected with Ad-SLPI-revCasp3 and Ad-SLPI-GFP at multiplicity of infection of 50 pfu per cell, respectively. After incubation for 72 h, the infected cells were harvested, and subjected to apoptosis analysis of DNA fragmentation and flow cytometry assays. The above assays were repeated three times.
In vivo experiment A total of 22 mice were subcutaneously injected with 0.2 ml cell suspension of Hep-2 (1 Â 10 7 ) in the right dorsal scapula region. The size of tumors was blindly measured with calipers every 3 days. When the tumor had reached the size of 50 --100 mm 3 , animals were randomized into three groups and treatment of intratumoral injection was initiated as follows: group 1 received Ad-SLPI-revCasp3 (1 Â 10 8 IU per 100 ml), group 2 received Ad-SLPI-GFP (1 Â 10 8 IU per 100 ml) and group 3 received PBS as control; all administrations were given every 3 days for a total of five doses. Tumor sizes were recorded blindly without the knowledge of the treatment groups. The volume of tumor was calculated using the simplified formula for a rotational ellipsoid V ¼ (ab 2 )/2 (a: major axis in mm; b: minor axis in mm). To assess the toxicity of the recombinant adenoviruses, mice were kept further to day 25 after the first administration of the viruses before finally killing the mice. The weight of both tumor and the liver were recorded. Randomly selected tumor and the liver samples from each group were fixed in formalin and paraffin embeded, and sections were subject to hematoxylin and eosin staining.
Statistics
Results were expressed as mean±s.d. One-way analysis of variance was used to compare the values of the different groups. A value of Po0.05 was considered as significant.
RESULTS
SLPI promoter selected as tissue-specific promoter in Hep-2 laryngeal carcinoma cells According to published literatures, three fragments of SLPI promoter (SLPIa, SLPIb and SLPIc ), 11 SCCA2 (À460 to 0) 5 and survivin (À1471 to À36) 12 genes were cloned by PCR and evaluated for their transcription activity. Dual-luciferase reporter assay showed that promoter SLPIb exhibited the highest transcription activity in Hep-2 cells among the promoters evaluated (Po0.05, one-way analysis of variance test) ( Table 2) , and also exhibited specific transcription activity in Hep-2 cells when compared with that in either HUVEC or MG-63 cells, with approximately 37-fold and 17-fold differences, respectively (Figure 1) , and was therefore selected as the tissue-specific promoter in Hep-2 laryngeal carcinoma cells in subsequent recombinant adenoviral vector construction.
Generation of the recombinant adenoviruses Ad-SLPI-revCasp3 and Ad-SLPI-GFP Shuttle plasmids pDC312-SLPI-Caspase-3-pA and pDC312-SLPI-GFP-pA were constructed with revCasp3 and GFP gene under the control of the above-determined SLPI promoter (SLPIb). Each of the shuttle plasmid was cotransfected with backbone plasmid pBGHlox(delta)E1,3Cre vector into HEK293 to generate replicationdeficient adenoviruses Ad-SLPI-revCasp3 or Ad-SLPI-GFP. Obvious cytopathic effect was observed in HEK293 in 2 weeks post transfection. Recombinant adenoviruses in culture supernatants were characterized by PCR with expected bands of 330 and 1482 bp for Ad-SLPI-revCasp3 and Ad-SLPI-GFP, respectively (Figures 2a and b) . Recombinant adenoviruses were propagated in large scale and purified by cesium chloride density gradient centrifugation. The titers of purified Ad-SLPI-revCasp3 and Ad-SLPI-GFP were 1 Â 10 9 and 6.3 Â 10 9 pfu ml
À1
, respectively, as determined by the method of TCID50. 13 Infection of Ad-SLPI-revCasp3 into Hep-2 cells resulted in the significantly increased 17-kd-cleaved endogenous caspase-3 (Figure 2c) , as expected by the successful expression of recombinant revCasp3, and strong signal of green fluorescence could also be seen in Hep-2 cells infected with Ad-SLPI-GFP, but no signal could be observed in HUVEC infected with Ad-SLPI-GFP (data not shown). These results convinced us for the specificity of SLPI promoter in further study of targeted gene therapy for laryngeal carcinoma.
Ad-SLPI-revCasp3 specifically inhibited human laryngeal carcinoma cell Hep-2 via inducing apoptosis in vitro MTT assay was used to evaluate the antiproliferative effect of Ad-SLPI-revCasp3. The proliferation of Hep-2 cells was markedly inhibited by Ad-SLPI-revCasp3 72 h post infection, whereas no significant inhibition was observed for HUVEC cells. The survival rate of Hep-2 cells (42.8±0.007%) was much lower than that of HUVEC cells (92.2 ± 0.146%) (Figure 3a) .
Hep-2 cells showed an obvious change in morphology 72 h after infection with Ad-SLPI-revCasp3: cells turned round and shrank, with some even floating in a cluster, a typical phenomenon of apoptosis, whereas no significant morphological change could be observed for the infected HUVEC cells (Figure 3b ). This apoptotic phenomenon was further confirmed by both flow cytometry and DNA fragmentation assays. Flow cytometry analysis was performed to evaluate the proportion of apoptosis with ApoScreen Annexin V Apoptosis kit. The proportion of late apoptosis for the Hep-2 cells infected by Ad-SLPI-revCasp3 was 80.6%, which was significantly higher than that by Ad-SLPI-GFP and PBS. No significant difference was observed in the infected HUVEC cells by Ad-SLPI-revCasp3, Ad-SLPI-GFP and the control PBS group (Figure 3c ). All these evidences confirmed that recombinant revCasp3 could efficiently induce apoptosis in laryngeal cancer cells, the apoptosis-inducing effect was specific to Hep-2 cells under the control of SLPI promoter. Noticeable DNA fragmentation was also observed for the infected Hep-2 cells by Ad-SLPI-revCasp3, which clearly indicated effective induction of apoptosis in laryngeal carcinoma cells, but none was observed for either HUVEC cells infected by Ad-SLPI-revCasp3, or for Hep-2 cells and HUVEC cells infected by Ad-SLPI-GFP (Figure 4) . This also showed that revCasp3 was a potent effector gene to induce apoptosis, whereas the adenoviral vector itself did not produce any obvious effect on cell apoptosis.
Antitumor effect of Ad-SLPI-revCasp3 on laryngeal carcinoma Hep-2 xenograft Ad-SLPI-revCasp3 specifically suppressed tumor growth in human laryngeal carcinoma Hep-2 xenograft without any obvious toxicity. The size of tumors was measured with calipers every 3 days after the first administration of recombinant adenoviruses. In vivo tumor growth rate was evaluated according to the calculated tumor volume, as described in methods. Statistical analysis showed that Ad-SLPI-revCasp3 achieved significant antitumor efficacy on the thirteenth and sixteenth day after first injection (Po0.05). However, by the end of the whole observation period (12 days after the last injection), the difference of the average tumor sizes and tumor weights among the three groups was not statistically significant (P40.05) (Figures 5a and b) , due to the residual tumor growth. Large area of typical necrotic appearance was observed in the paraffin sections from tumor tissues of the Ad-SLPI-revCasp3-treated group by HE staining. However, there was no necrosis in large area in the other two control groups treated with Ad-SLPI-GFP and PBS (Figure 6a) . All of the three groups survived in good condition without significant difference in the activities, diets or body weight (Figures 5c and d) . No obvious liver toxicity, as referred to degeneration and necrosis, was observed in the adenovirus-treated group, as compared with the control groups (Figure 6b ).
DISCUSSION
Recent studies have shown that successful cancer gene therapy requires several important aspects working together to kill tumor cells specifically, while maintaining normal cell function and tissue integrity, 14 which include effective system for targeting gene delivery into tumor cells and potent therapeutic genes to induce efficient apoptosis under accurate control.
So far, the strategy to apply tissue-specific promoters as gene expression modulator is one of the most effective ways for targeting gene therapy, such as alpha fetoprotein gene promoter for hepatocyte carcinoma, prostate-specific antigen gene promoter in the targeting gene therapy for prostate cancer, SLPI promoter for ovarian cancer. 4, 15, 16 In the current study, the transcription efficiency of SLPIb promoter (À650 to þ 22) was the highest among all candidate promoters in laryngeal carcinoma Hep-2 cell but very low in human vein endothelial cell HUVEC and osteosarcoma MG-63 cells, indicating this SLPIb promoter was an efficient and tissue-specific promoter for human laryngeal squamous cell carcinoma cell line Hep-2. As no targeted gene therapy for laryngeal carcinoma has been investigated before, this is the first attempt in this area with this strategy.
It is of great importance to choose an appropriate therapeutic gene in cancer gene therapy, which usually includes tumorsuppressor gene, cytokines and suicide genes. 2,17 --23 Inhibition of tumor growth can be achieved by introducing the above genes. However, the therapeutic efficacy of these genes is often limited, as the development and progression of cancer is the accumulated effect of multiple gene defects. Recent development in cancer gene therapy have demonstrated that one of the most effective way to improve the therapeutic efficiency is to induce apoptosis by targeting the apoptosis pathway. Caspase-dependent apoptosis is one of the major pathway for apoptosis of most cells, in which caspase-3 has a major role as an executioner caspase after being activated from its zymogen form by other initiator caspases when apoptotic signaling is triggered, and this makes active caspase 3 a potent candidate in cancer gene therapy as an apoptosis-executing factor. In the current study, an obvious phenomenon of apoptosis induced by the constitutively active recombinant caspase-3 (revCasp3) was observed. The advantage of choosing active caspase 3 as the therapeutic gene is that activation of caspase 3 is the final 'no-return' step in caspase-dependent apoptosis---once activated, apoptosis will definitely occur. Compared with other strategies of cancer gene therapy such as forced expression of tumor-suppressor genes or the suicide genes, revCasp3 can directly induce apoptosis without any other additional conditions such as the genetic/epigenetic background of cancer cells or administration of prodrugs.
Delivered by replication-deficient adenoviral vector, expression of revCasp3 controlled by SLPI promoter showed growth suppression and local necrosis of human laryngeal carcinoma Hep-2 xenografts in nude mice in this study. Administration of the recombinant adenovirus didn't show any systemic adverse effect, without influence on the general condition or any obvious toxicity to the liver. However, the residue tumor in the Ad-SLPI-revCasp3-treated group showed progression when administration of therapeutic virus stopped, as shown by the growth curve in Figure 5a , suggesting the necessity for additional dosage and/or an appropriate timing for treatment worth exploring in future work.
As one of the most efficient vectors for gene delivery and expression, replication-deficient recombinant adenovirus was used in the current work, although it is not the only candidate gene carrier suitable in cancer gene therapy. Non-viral vectors and other viral vectors, such as the adeno-associated virus or lentivirus, may also be good candidates for such a study. 24 With the consideration of the tropism towards the laryngeal mucosa, safety for its non-integration into genome of host cells, easy manipulation in vector packaging and high titer in virus preparation (10 12 --10 13 pfu ml À1 ), 14 we used adenovirus just as a gene delivery vector in our study.
As the development and progression of cancer is a multi-step process with multiple genetic/epigenetic alterations, one therapeutic gene is often insufficient to completely overcome the disease. Multi-target gene therapy strategy is the trend to improve the therapeutic efficacy for inducing apoptosis efficiently in the development of cancer gene therapeutics. Combination of revCasp3 and target genes including other apoptosisinducing factors involved in caspase-dependent or caspaseindependent pathways, 25 --27 such as Granzyme B, AIF, Bid and so on, will increase the apoptosis of target cells. Another way to improve the therapeutic effect is to introduce some transcriptional regulatory elements, such as the CMV enhancer, 28 which may significantly increase the transcriptional activity of SLPI promoter while maintaining its tissue specificity. For gene therapy of head and neck squamous cell carcinoma specifically, application of inducible promoters such as Egr-1, which may increase the transcriptional efficiency in response to the radiotherapy, 29 is also a promising approach. The comprehensive application of gene therapy with traditional methods such as surgery, radiotherapy and/or chemotherapy is the direction for future management to improve the outcomes for patients with laryngeal carcinoma.
Although it has not yet been approved for any cancer gene therapy by FDA, many novel protocols for targeted cancer gene therapy are under clinical trails of phase I or phase II. 30, 31 Specific expression of recombinant active caspase-3 under the control of SLPI promoter for the specific induction of apoptosis is a new attempt for targeted gene therapy in laryngeal carcinoma. With regards to better therapeutic efficacy, the selection/combined use of more potent therapeutic genes, as well as a suitable strategy for comprehensive therapy, are worthy of investigation in our futher work.
